Immunoblotting demonstrated weaker CD133 protein bands in HT29 tumor tissue of mice treated with celecoxib (67.5 ± 7.8% of controls) compared to stronger CD133 protein bands in tumor tissue of vehicle-treated controls (P < 0.005; Figures 6(a) and 6(b)). This evidence concerns the gene PROM1 and neoplasm.